Wegovy users have five times greater risk of sudden sight loss than Ozempic users - study

'Eye strokes' cause sudden and usually permanent vision loss due to reduced blood flow to the optic nerve

Patients taking Wegovy for weight loss had a fivefold greater chance of developing non-arteritic anterior ischemic optic neuropathy (Naion) than the diabetes drug Ozempic, while men had a three times greater risk than women.

Patients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found.

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines such as semaglutide (sold as Wegovy, Ozempic, and Rybelsus) and tirzepetide (sold as Mounjaro) help reduce blood sugar levels, slow digestion, and reduce appetite, and have been linked to reduced risks of heart attack, fewer drug overdoses, and other health benefits.